Sedana Medical AB
Sedana Medical AB (publ), a medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Germany, and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-S, which are disposable medical devices that enable the administration of volatile anaesthetics; Sedaconda Syringe, a 50/60ml syringe; Sedaconda ACD starter kit; S… Read more
Sedana Medical AB (SEDANA) - Net Assets
Latest net assets as of December 2025: Skr900.78 Million SEK
Based on the latest financial reports, Sedana Medical AB (SEDANA) has net assets worth Skr900.78 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr954.46 Million) and total liabilities (Skr53.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr900.78 Million |
| % of Total Assets | 94.38% |
| Annual Growth Rate | 113.94% |
| 5-Year Change | -18.22% |
| 10-Year Change | 71277.26% |
| Growth Volatility | 2721.09 |
Sedana Medical AB - Net Assets Trend (2015–2025)
This chart illustrates how Sedana Medical AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sedana Medical AB (2015–2025)
The table below shows the annual net assets of Sedana Medical AB from 2015 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr900.78 Million | -6.00% |
| 2024-12-31 | Skr958.23 Million | -1.21% |
| 2023-12-31 | Skr970.00 Million | -5.75% |
| 2022-12-31 | Skr1.03 Billion | -6.56% |
| 2021-12-31 | Skr1.10 Billion | +99.87% |
| 2020-12-31 | Skr551.09 Million | -3.21% |
| 2019-12-31 | Skr569.38 Million | +161.41% |
| 2018-12-31 | Skr217.81 Million | +87.12% |
| 2017-12-31 | Skr116.40 Million | +9123.72% |
| 2016-12-31 | Skr1.26 Million | +181.70% |
| 2015-12-31 | Skr448.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sedana Medical AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 32664300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr2.48 Million | 0.28% |
| Other Comprehensive Income | Skr-3.73 Million | -0.41% |
| Other Components | Skr1.23 Billion | 136.40% |
| Total Equity | Skr900.78 Million | 100.00% |
Sedana Medical AB Competitors by Market Cap
The table below lists competitors of Sedana Medical AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pinetree Capital Ltd
PINK:PNPFF
|
$54.36 Million |
|
Resurs Holding AB
ST:RESURS
|
$54.36 Million |
|
Compagnie Du Mont-Blanc
PA:MLCMB
|
$54.37 Million |
|
Jonestown Bank and Trust Co of Jonestown Pennsylvania
OTCQX:JBTC
|
$54.39 Million |
|
Polytec Holding AG
VI:PYT
|
$54.33 Million |
|
ALCAT
PA:ALCAT
|
$54.31 Million |
|
Oak Ridge Financial Services Inc
PINK:BKOR
|
$54.31 Million |
|
New Best Wire Industrial Co Ltd
TWO:5013
|
$54.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sedana Medical AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 958,227,000 to 900,781,000, a change of -57,446,000 (-6.0%).
- Net loss of 59,244,000 reduced equity.
- Other comprehensive income increased equity by 60,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-59.24 Million | -6.58% |
| Other Comprehensive Income | Skr60.00K | +0.01% |
| Other Changes | Skr1.74 Million | +0.19% |
| Total Change | Skr- | -6.00% |
Book Value vs Market Value Analysis
This analysis compares Sedana Medical AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.02x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1416.11x to 1.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | Skr0.01 | Skr9.29 | x |
| 2016-12-31 | Skr0.02 | Skr9.29 | x |
| 2017-12-31 | Skr1.70 | Skr9.29 | x |
| 2018-12-31 | Skr2.84 | Skr9.29 | x |
| 2019-12-31 | Skr6.80 | Skr9.29 | x |
| 2020-12-31 | Skr6.02 | Skr9.29 | x |
| 2021-12-31 | Skr11.87 | Skr9.29 | x |
| 2022-12-31 | Skr10.36 | Skr9.29 | x |
| 2023-12-31 | Skr9.76 | Skr9.29 | x |
| 2024-12-31 | Skr9.65 | Skr9.29 | x |
| 2025-12-31 | Skr9.07 | Skr9.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sedana Medical AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -29.59%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.06x
- Recent ROE (-6.58%) is above the historical average (-18.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -268.97% | -4.29% | 2.27x | 27.68x | Skr-1.25 Million |
| 2016 | 101.90% | 4.00% | 1.40x | 18.15x | Skr1.16 Million |
| 2017 | -3.33% | -9.59% | 0.31x | 1.13x | Skr-15.52 Million |
| 2018 | -3.15% | -11.86% | 0.25x | 1.06x | Skr-28.65 Million |
| 2019 | -2.87% | -22.83% | 0.12x | 1.04x | Skr-73.30 Million |
| 2020 | -4.92% | -19.14% | 0.24x | 1.09x | Skr-82.25 Million |
| 2021 | -5.26% | -36.42% | 0.14x | 1.06x | Skr-168.11 Million |
| 2022 | -7.14% | -59.83% | 0.11x | 1.05x | Skr-176.42 Million |
| 2023 | -6.15% | -38.74% | 0.15x | 1.05x | Skr-156.61 Million |
| 2024 | -1.11% | -5.97% | 0.18x | 1.06x | Skr-106.50 Million |
| 2025 | -6.58% | -29.59% | 0.21x | 1.06x | Skr-149.32 Million |
Industry Comparison
This section compares Sedana Medical AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $88,444,177
- Average return on equity (ROE) among peers: -99.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sedana Medical AB (SEDANA) | Skr900.78 Million | -268.97% | 0.06x | $54.35 Million |
| Acarix A/S (ACARIX) | $51.83 Million | -148.55% | 0.34x | $28.86 Million |
| Arcoma AB (ARCOMA) | $39.03 Million | -4.06% | 0.95x | $8.51 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $144.60 Million | -26.53% | 3.87x | $19.62 Million |
| CellaVision AB (CEVI) | $124.91 Million | 5.16% | 0.43x | $263.99 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $17.06 Million | -157.93% | 0.60x | $13.31 Million |
| Chordate Medical Holding AB (CMH) | $25.64 Million | -77.06% | 0.22x | $17.64K |
| Coala Life Group AB (COALA) | $39.33 Million | -360.87% | 1.68x | $468.93K |
| C-Rad AB (publ) (CRAD-B) | $347.20 Million | 3.02% | 0.44x | $55.46 Million |
| Duearity AB (DEAR) | $11.04 Million | -140.58% | 0.46x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $83.80 Million | -90.69% | 0.17x | $5.40 Million |